Shahin Gharakhanian statement in the latest Press Release from InnaVirVax issued during the Conference on Retroviruses, 3-6 March 2013, Atlanta GA, USA. Reference: Katlama Ch, Launay O, Ho Tsong Fang R, Bodilis H, Calin R, Autran B, Gharakhanian S, Vieillard V, J Crouzet J, Debré P. A randomized, placebo-controlled, double-blind, phase I/IIa...

Potential role of anti-3S antibodies in an HIV medical cure strategy ?

February 4, 2013

Crouzet J, Vieillard V, Debré P, Katlama C, Launay O, Ho Tsong Fang R, Desfontaines-Batéjat D, Marcu M, Gharakhanian S. Potential role of anti-3S antibodies in an HIV medical cure strategy ?. Oral/Poster Presentation. HIV Cure & Eradication Workshop, 24-25 January 2013; Milan, Italy . [Poster: distinguished as best poster of the Workshop]. We...

Course Leader for a New Seminar for Biotech and Pharma in Boston

December 16, 2012

“Launching a High-Value Medical & Scientific Affairs Team” Medical & Scientific Affairs Seminar Boston Jan 2013

InnaVirVax Press Release on World AIDS Day

December 16, 2012

InnaVirVax: the Phase I/IIa clinical study of its VAC-3S immunotherapeutic vaccine in the treatment of HIV infection has achieved its primary endpoint InnaVirVax Press Release 30NOV2012

Selection of Recent Lectures by S Gharakhanian

September 28, 2012

Clinical Development in Chronic Viral Disease:Reflections and Experiences from Hepatitis C and HIV Infection. Lecture @ Division of Infectious Diseases, Brigham & Womans Hospital, Harvard Medical School, 30 July 2012 Valuable role of medical affairs in new drug approval and launch Medical Affairs Executive Forum, 12-13 April 2012, Morristown NJ. https://exlpharma.boxenterprise.net/medical...